SOP for Pediatric Safeguards (Age-Appropriate Procedures/Assent)

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-pediatric-safeguards-age-appropriate-procedures-assent”
},
“headline”: “SOP for Pediatric Safeguards (Age-Appropriate Procedures/Assent)”,
“description”: “This SOP defines standardized procedures for pediatric safeguards in clinical trials, including age-appropriate assent, parental consent, and risk minimization strategies. It ensures compliance with FDA, EMA, CDSCO, WHO, and ICH GCP regulations for pediatric research.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Published on 22/12/2025

Standard Operating Procedure for Pediatric Safeguards (Age-Appropriate Procedures/Assent)

SOP No.	CR/OPS/119/2025
Supersedes	NA
Page No.	1 of 63
Issue Date	26/08/2025
Effective Date	01/09/2025
Review Date	01/09/2026

Table of Contents

Purpose

The purpose of this SOP is to define pediatric safeguards in clinical trials to ensure ethical conduct, subject safety, and regulatory compliance. It provides procedures for obtaining parental consent

and age-appropriate assent, implementing child-centered trial procedures, and ensuring oversight for pediatric research.

Scope

This SOP applies to sponsors, investigators, CROs, ECs/IRBs, and site staff involved in pediatric clinical trials. It covers informed consent, assent, communication, risk minimization, safeguarding vulnerable populations, trial-specific adjustments, and long-term follow-up of pediatric subjects.

Responsibilities

Sponsor: Ensures pediatric trial designs incorporate safeguards and complies with international guidelines.
Investigator: Obtains parental consent and subject assent; ensures child-friendly procedures.
Site Staff: Communicate with children using age-appropriate language and safeguard rights.
EC/IRB: Reviews pediatric safeguards during protocol approval.
CRO: Monitors pediatric safeguards across sites.
QA: Audits pediatric trial conduct for compliance.

Accountability

The Principal Investigator is accountable for ensuring pediatric safeguards at the site. The Sponsor is accountable for oversight and regulatory submissions related to pediatric safeguards.

Procedure

1. Parental Consent
1.1 Obtain informed consent from parents or legal guardians before subject enrollment.
1.2 Use language understandable to parents/guardians.
1.3 Document in Parental Consent Log (Annexure-1).

2. Age-Appropriate Assent
2.1 Children capable of understanding (usually 7 years and older) must provide assent.
2.2 Use age-appropriate forms and verbal explanations.
2.3 Document in Assent Log (Annexure-2).

3. Child-Friendly Trial Procedures
3.1 Adapt procedures (e.g., blood draw volumes, dosing) for pediatric populations.
3.2 Use child-appropriate equipment and comfort measures.
3.3 Record adjustments in Pediatric Procedures Log (Annexure-3).

4. Communication with Children
4.1 Use simple, non-technical language appropriate for age.
4.2 Provide information materials (visual aids, child-friendly documents).
4.3 Document in Communication Log (Annexure-4).

5. Risk Minimization
5.1 Implement strategies to minimize pain, anxiety, and risk.
5.2 Document in Risk Minimization Log (Annexure-5).

6. Oversight and Monitoring
6.1 EC/IRB must specifically review pediatric safeguards in protocols.
6.2 Sponsor and CRO to conduct monitoring and audits.
6.3 Document in Oversight Log (Annexure-6).

7. Long-Term Follow-Up
7.1 Conduct long-term follow-up if required for developmental or safety assessments.
7.2 Document in Pediatric Follow-Up Log (Annexure-7).

8. Archiving
8.1 Archive all pediatric safeguard records in TMF and ISF.
8.2 Retain per regulatory requirements (minimum 15–25 years).

Abbreviations

SOP: Standard Operating Procedure
CRO: Contract Research Organization
EC/IRB: Ethics Committee/Institutional Review Board
QA: Quality Assurance
IP: Investigational Product
TMF: Trial Master File
ISF: Investigator Site File
GCP: Good Clinical Practice
FDA: Food and Drug Administration
EMA: European Medicines Agency
CDSCO: Central Drugs Standard Control Organization
WHO: World Health Organization

Documents

Parental Consent Log (Annexure-1)
Assent Log (Annexure-2)
Pediatric Procedures Log (Annexure-3)
Communication Log (Annexure-4)
Risk Minimization Log (Annexure-5)
Oversight Log (Annexure-6)
Pediatric Follow-Up Log (Annexure-7)

References

Version: 1.0

Approval Section

Prepared By	Ravi Kumar, Pediatric Specialist
Checked By	Sunita Reddy, QA Officer
Approved By	Dr. Anil Sharma, Head Clinical Operations

Annexures

Annexure-1: Parental Consent Log

Date	Subject ID	Consent Obtained From	Investigator	Status
01/09/2025	PED-101	Parent/Guardian	Investigator	Signed

Annexure-2: Assent Log

Date	Subject ID	Age	Assent Obtained	By Whom
01/09/2025	PED-101	10	Yes	Study Nurse

Annexure-3: Pediatric Procedures Log

Blood Draw

Date	Subject ID	Procedure	Adjustment	Performed By
02/09/2025	PED-101	Reduced volume	Lab Technician

Annexure-4: Communication Log

Date	Subject ID	Mode	Summary	By Whom
03/09/2025	PED-101	Visual Aid	Explained procedure with pictures	Study Nurse

Annexure-5: Risk Minimization Log

Date	Subject ID	Risk Minimization Measure	Performed By	Status
04/09/2025	PED-101	Distraction techniques during procedure	Nurse	Effective

Annexure-6: Oversight Log

Date	Protocol ID	EC/IRB Review	Outcome	Approved By
05/09/2025	PED-TRIAL-01	Yes	Approved	EC Chair

Annexure-7: Pediatric Follow-Up Log

Date	Subject ID	Follow-Up Type	Performed By	Status
06/09/2025	PED-101	Developmental Check	Investigator	Completed

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
26/08/2025	00	Initial version	New SOP creation	Head Clinical Operations

For more SOPs visit: Pharma SOP